Maximising commercial value across the product lifecycle. Strategic insights and planning to drive commercial success at every stage.
GRA delivers business intelligence and strategic planning to support clients across all commercial aspects of their programs. Whether it's ensuring robust preparedness for fundraising discussions or facilitating successful licensing agreements, our specific expertise in performing risk-adjusted Net Present Value (rNPV) assessments, which account for the inherent uncertainties of drug development, provides a crucial advantage.
Portfolio Development: We enable clients to strategically develop and optimise their product portfolios through:
- Market and competitive landscape analysis.
- Identification of in- and out-licensing opportunities.
- Product pipeline evaluation and strategic prioritisation.
- Competition analysis and product pricing strategies.
- rNPV valuations for informed decision making.
Due Diligence: Our comprehensive opportunity evaluation encompasses technical due diligence for potential investments, extending to the detailed assessment of business plans, technical aspects, and market opportunities. Furthermore, we expertly support companies undergoing due diligence by preparing and managing secure data rooms.
Contract Services: We provide expert support to clients in the negotiation of a wide range of commercial agreements. This includes facilitating both in-licensing and out-licensing of valuable assets within your portfolio. Additionally, we expertly assist in the discussions and negotiations of critical supply agreements, covering both clinical and commercial needs.
Beyond direct project support, our expertise extends to providing strategic guidance at a high level. We can serve as non-executive board members, offering valuable commercial insights. Furthermore, our team can contribute expert input as members of your scientific advisory boards.